key: cord-0729841-3fr5tugk authors: Srivastava, K.; West, K. A.; De Giorgi, V.; Holbrook, M. R.; Bovin, N. V.; Henry, S. M.; Flegel, W. A. title: COVID-19 antibody detection and assay performance using red cell agglutination date: 2021-06-12 journal: nan DOI: 10.1101/2021.06.09.21258232 sha: 07be5bd195818c6484a066d1165a7bcb52229bb9 doc_id: 729841 cord_uid: 3fr5tugk Red cells can be labelled with peptides from the SARS-CoV-2 spike protein and used for serologic screening of SARS-CoV-2 antibodies. We evaluated 140 convalescent COVID-19 patients and 275 healthy controls using this C19-kodecyte assay. The analytical performance of the new assay was compared with a virus neutralizing assay and 2 commercial chemiluminescent antibody tests (Total assay and IgG assay, Ortho). The C19-kodecyte assay detected SARS-CoV-2 antibodies with a sensitivity of 92.8% and specificity of 96.3%, well within the minimum performance range required by FDA for EUA authorization of serologic tests. The Cohen's kappa coefficient was 0.90 indicating an almost perfect agreement with the Total assay. The Pearson correlation coefficient was 0.20 with the neutralizing assay (0.49 with IgG, and 0.41 with Total assays). The limited correlation in assay reaction strengths suggested that the assays may detect different antibody specificities. Our easily scalable C19-kodecyte assay may vastly improve test capacity in blood typing laboratories using their routine setups for column agglutination technique. The coronavirus disease 2019 (COVID-19) pandemic, caused by the novel 60 betacoronavirus SARS-CoV-2, has resulted in global public health crisis. As of May 27 2021, 61 there have been more than 168 million confirmed cases of COVID-19, including more than 3 62 million deaths reported globally [1] . Vaccines against SARS-CoV-2 were first approved in 63 China on June 25, 2020 for limited use in the military [2], followed by Russia on August 11, 64 2020 for emergency use [3] . These serologic assays are also used to identify asymptomatic individuals, evaluate immune 79 response in patients, identify of high-titer CCP units, determine duration and magnitude of 80 immunity conferred by SARS-CoV-2 vaccine, and assist in the prediction of disease 81 progression and epidemiology [10, 11] . The FDA has approved 79 SARS-CoV-2 antibody 82 for use under a CC0 license. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 12, 2021. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 12, 2021. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Table S1 This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 12, 2021. Table S3 ). 201 With positive and negative data available only for the C19-kodecyte and Ortho Total assays, 202 the agreement between the 2 assays was considered as almost perfect [21] This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 12, 2021. ; https://doi.org/10.1101/2021.06.09.21258232 doi: medRxiv preprint The SARS-CoV-2 kodecyte based antibody diagnostic assay is a simple test for rapid 213 screening of SARS-CoV-2 antibodies in human plasma [13] . The assay can be easily 214 established in a blood bank, using its typical equipment, and is well suited for surveillance 215 studies. We compared the C19-kodecyte assay with 2 established commercial assays (Ortho 216 Total and Ortho IgG) and an in-house developed virus neutralization assay. All 4 assays 217 detect antibodies directed against the SARS-CoV-2 spike glycoprotein [13, 15, 16] . This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 12, 2021. The C19-kodecyte assay, although a beta version with a possibility of further 250 refinement, is comparable to other FDA authorized or approved assays. However, an 251 optimization can still be attempted and improvements seem achievable for sensitivity and 252 specificity by adjusting the sequence of peptides and the FSL construct concentrations. 253 Slightly changing the existing peptide sequences by shifting or elongating them either left or 254 right into the flanking sequences has the potential to improve both sensitivity and specificity 255 [33]. Alternatively, different peptides could be evaluated and when testing CCP samples with 256 a different SARS-CoV-2 spike protein sequence (Peptide 808), 3 samples that tested false 257 negative in the C19-kodecyte assay tested positive with Peptide 808-kodecyte assay 258 (Supplementary Table S3 ). Likewise, optimization of the concentration of peptides during 259 kodecyte preparation can also improve reaction specificity of the assay. 260 for use under a CC0 license. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 12, 2021. ; https://doi.org/10.1101/2021.06.09.21258232 doi: medRxiv preprint The unusually flexibility of the C19-kodecyte assay can easily be adapted using 261 different peptides from the SARS-CoV-2 spike and nucleocapsid proteins. This approach 262 allows to modify the assay specificity to determine the duration and magnitude of immunity 263 conferred by SARS-CoV-2 vaccine which would be an advantage for population surveillance 264 for ongoing infection and maintenance of immunity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 12, 2021. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 12, 2021. COVID-19) dashboard. Geneva: World Health Organization CanSino's COVID-19 vaccine candidate approved for military use in China Putin says Russia has approved 'world first' Covid-19 vaccine FDA. Pfizer-BioNTech COVID-19 vaccine COVID-19 vaccine tracker Emergency Use Authorization for COVID-19 Convalescent Plasma (originally issued Aug 23, 2020, and subsequently reissued with revisions) available at Convalescent plasma in Covid-19: possible 340 mechanisms of action Association of convalescent plasma treatment with 344 clinical outcomes in patients with COVID-19: a systematic review and meta-analysis Brief: FDA updates Emergency Use Authorization for COVID-19 347 convalescent plasma to reflect new data COVID-19 antibody tests: a valuable 351 public health tool with limited relevance to individuals 354 authorizations-medical-devices/in-vitro-diagnostics-euas-serology-and-other-adaptive-355 immune-response-tests-sars-cov-2 COVID-19 antibody screening with SARS CoV-2 red cell kodecytes using routine serologic diagnostic platforms Anti-SARS-CoV-2 serology persistence over 360 time in COVID-19 convalescent plasma donors Analytical and clinical performances of five 362 Scalable, micro-neutralization assay for 367 qualitative assessment of SARS-CoV-2 (COVID-19) virus-neutralizing antibodies in human 368 clinical samples Marsh WL. Scoring of hemagglutination reactions Two-sided confidence intervals for the single proportion: comparison of 371 seven methods A coefficient of agreement for nominal scales The measurement of observer agreement for categorical data SARS-CoV-2 peptide bioconjugates designed 377 for antibody diagnostics Decrease in serum antibodies to SARS-CoV-2 in 379 convalescent plasma donors over time Antibody titers against SARS-CoV-2 decline, but 381 do not disappear for several months Robust neutralizing antibodies to SARS-CoV-2 383 infection persist for months Waning of SARS-CoV-2 RBD antibodies in 385 longitudinal convalescent plasma samples within 4 months after symptom onset SARS-CoV-2 infections and serologic 392 responses from a sample of U.S. navy service members -USS Theodore Roosevelt COVID-19 and postinfection immunity: limited 395 evidence, many remaining questions Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications Template for test developers of serology tests that detect or correlate to neutralizing 400 antibodies Novel antibody screening cells, MUT+Mur 402 kodecytes, created by attaching peptides onto red blood cells It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted